Sanofi Eligible for $200M in Launch Milestones in Expanded Matrix-M Deal
Sanofi earned $225 million in 2025 milestones from Matrix-M licensing and expanded the adjuvant into its BARDA-funded pandemic flu candidate. The collaboration now triggers a $125 million Phase 3 study payment and offers up to $200 million in launch milestones plus mid-single-digit royalties per vaccine.
1. Sanofi Achieves $225M in Matrix-M Milestones
In 2025 Sanofi fulfilled all $225 million in eligible milestones under its Matrix-M licensing agreement by hitting development and sales targets, demonstrating strong progress in its adjuvant partnership model.
2. Expanded Flu Candidate and Future Revenue Potential
Sanofi expanded Matrix-M into its BARDA-funded pandemic flu candidate, securing a $125 million payment upon Phase 3 study initiation and positioning itself to earn up to $200 million in launch and sales milestones plus mid-single-digit royalties on each vaccine.